Recombinant Human Kallikrein 11 is produced with our mammalian expression system in human cells. The target protein is expressed with sequence (Glu19-Asn250) of Human KLK11 fused with a polyhistidine tag at the C-terminus.
Pureté
> 95 % as determined by reducing SDS-PAGE.
Stérilité
0.2 μm filtered
niveau d'endotoxine
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
KLK11
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 80 % as determined by SDS-PAGE and Coomassie blue staining
AbP, STD
Restrictions
For Research Use only
Format
Liquid
Reconstitution
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Buffer
Supplied as a 0.2 μm filtered solution of 20 mM TrisHCl, 150 mM NaCl, 2 mM CaCl2, pH 8.0.
Conseil sur la manipulation
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Stock
-80 °C
Stockage commentaire
Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
Human Kallikrein 11 (KLK11) is a member of tissue kallikrein family which are extracellular serine proteases consisting of 15 members. Two isoforms of KLK11 are differentially expressed. Isoform 1 is predominantly expressed in brain and isoform 2 is preferentially expressed in prostate. Isoform 1 consists of a signal peptide,a short pro peptide and the mature chain.Isoform 2 contains an extra 32 amino acid N terminal to full-length isoform 1.KLK11 is a novel marker for ovarian and prostate cancer carcinomas. KLK11 can be activated by thermolysin and is active against a thioester substrate. Alternative Names: Kallikrein-11, hK11, Hippostasin, Serine Protease 20, Trypsin-Like Protease, KLK11, PRSS20, TLSP